Form 4: Catalyst Pharmaceuticals CEO Richard Daly Reports Stock Transactions
SEC Form 4 Filing
Richard Daly, CEO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On February 14, 2025, Richard Daly, the President and CEO of Catalyst Pharmaceuticals, had 4,000 restricted stock units vest, which converted into common stock.
- The company withheld 1,574 shares to cover applicable withholding taxes.
- Following these transactions, Daly directly owns 269,764 shares of Catalyst Pharmaceuticals common stock and 2,234,753 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction affects the CEO's ownership stake in the company, which is of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/14/2023 | 1/3rd of derivative securities vested |
| 02/14/2024 | 1/3rd of derivative securities vested |
| 02/14/2025 | Restricted stock units vested; shares delivered; tax withholding occurred |
| 02/19/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.